Los Angeles Capital Management
FBIO icon

Los Angeles Capital Management’s Fortress Biotech FBIO Stock Holding History

Los Angeles Capital Management’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,353
Closed -$126K – 1511
2021
Q2 		$126K Sell
2,353
-146
-6% -$8.81K ﹤0.01% 1505
2021
Q1 		$132K Sell
2,499
-1,464
-37% -$82.6K ﹤0.01% 1561
2020
Q4 		$188K Buy
+3,963
New +$172K ﹤0.01% 1476

Other funds holding FBIO

Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
CL
CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Los Angeles Capital Management's FBIO Position: Q3 2021 in Review

Los Angeles Capital Management sold out of Fortress Biotech (FBIO) in Q3 2021, closing a stake of 2,353 shares — an estimated $126K sold.

Los Angeles Capital Management first reported a position in FBIO in Q4 2020 and held it in 3 quarters. The position peaked at $188K in Q4 2020. 79 funds tracked by Wall St. Rank hold FBIO as of Q3 2021.

  • Los Angeles Capital Management reported no remaining Fortress Biotech position as of Q3 2021 after selling out during the quarter.
  • Los Angeles Capital Management sold 2,353 Fortress Biotech shares in Q3 2021, an estimated $126K.
  • Los Angeles Capital Management first reported a position in Fortress Biotech in Q4 2020 and held it in 3 quarters.
  • Los Angeles Capital Management's Fortress Biotech position peaked at $188K in Q4 2020.
  • 79 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2021.

Based on Los Angeles Capital Management's 13F filing for Q3 2021, filed 5 Nov 2021.